For medicinal products included in
a reference group that are not granted a reimbursement amount or conditions
beyond those of interchangeable products, a cost-effectiveness analysis is not
required. Newly, however, a budget impact analysis (BIA) must be submitted including
a calculation of deductible co-payments.
According to the State Institute
for Drug Control (SÚKL),...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
